SK288007B6 - Multivalent vaccine composition, process for its producing, and its use - Google Patents
Multivalent vaccine composition, process for its producing, and its use Download PDFInfo
- Publication number
- SK288007B6 SK288007B6 SK1843-2002A SK18432002A SK288007B6 SK 288007 B6 SK288007 B6 SK 288007B6 SK 18432002 A SK18432002 A SK 18432002A SK 288007 B6 SK288007 B6 SK 288007B6
- Authority
- SK
- Slovakia
- Prior art keywords
- polysaccharide
- envelope
- group
- pneumoniae serotype
- immunogenic composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title abstract description 15
- 229940031348 multivalent vaccine Drugs 0.000 title description 2
- 239000005017 polysaccharide Substances 0.000 claims abstract description 156
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 154
- 150000004676 glycans Chemical class 0.000 claims abstract description 60
- 230000002163 immunogen Effects 0.000 claims abstract description 35
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 35
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 35
- 241000606768 Haemophilus influenzae Species 0.000 claims abstract description 32
- 230000001580 bacterial effect Effects 0.000 claims abstract description 30
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 19
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 19
- 230000004224 protection Effects 0.000 claims abstract description 11
- 208000015181 infectious disease Diseases 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 241000588650 Neisseria meningitidis Species 0.000 claims description 31
- 229960000814 tetanus toxoid Drugs 0.000 claims description 27
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 18
- 101710188053 Protein D Proteins 0.000 claims description 18
- 101710132893 Resolvase Proteins 0.000 claims description 18
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 14
- 230000000405 serological effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 6
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 6
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 241000194017 Streptococcus Species 0.000 claims description 4
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
- 101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 claims description 2
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 2
- 101710183389 Pneumolysin Proteins 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 5
- 150000004804 polysaccharides Chemical class 0.000 description 97
- 229960005486 vaccine Drugs 0.000 description 62
- 102000036639 antigens Human genes 0.000 description 32
- 108091007433 antigens Proteins 0.000 description 32
- 239000000427 antigen Substances 0.000 description 31
- 239000002671 adjuvant Substances 0.000 description 19
- 238000009472 formulation Methods 0.000 description 18
- 241000588832 Bordetella pertussis Species 0.000 description 12
- 229940124885 Hiberix Drugs 0.000 description 12
- 108700020122 Hiberix Proteins 0.000 description 11
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 241000700721 Hepatitis B virus Species 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 229910052782 aluminium Inorganic materials 0.000 description 7
- 229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 7
- 241000193449 Clostridium tetani Species 0.000 description 6
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 6
- 201000005702 Pertussis Diseases 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- -1 1-cyano-dimethylaminopyridinium tetrafluoroborate Chemical compound 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000002480 immunoprotective effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108010021711 pertactin Proteins 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940001442 combination vaccine Drugs 0.000 description 2
- 229940031670 conjugate vaccine Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 229940124914 Havrix Drugs 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010065838 Middle ear inflammation Diseases 0.000 description 1
- 241000921898 Neisseria meningitidis serogroup A Species 0.000 description 1
- 101100521383 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prp-5 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 229920001586 anionic polysaccharide Polymers 0.000 description 1
- 150000004836 anionic polysaccharides Chemical class 0.000 description 1
- 230000003497 anti-pneumococcal effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940014135 meningitis vaccine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 1
- 229940124733 pneumococcal vaccine Drugs 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0015999.6A GB0015999D0 (en) | 2000-06-29 | 2000-06-29 | Novel compounds |
| GB0108363A GB0108363D0 (en) | 2001-04-03 | 2001-04-03 | Vaccine composition |
| GBGB0108364.1A GB0108364D0 (en) | 2001-04-03 | 2001-04-03 | Vaccine composition |
| PCT/EP2001/007288 WO2002000249A2 (en) | 2000-06-29 | 2001-06-27 | Multivalent vaccine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK18432002A3 SK18432002A3 (sk) | 2003-08-05 |
| SK288007B6 true SK288007B6 (sk) | 2012-10-02 |
Family
ID=27255788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1843-2002A SK288007B6 (sk) | 2000-06-29 | 2001-06-27 | Multivalent vaccine composition, process for its producing, and its use |
Country Status (34)
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4540795B2 (ja) * | 2000-03-10 | 2010-09-08 | 一般財団法人阪大微生物病研究会 | 生ワクチンの細胞性免疫活性を不活化ワクチンにも起こさせる方法、及びこれより得られる混合ワクチン |
| CZ20024224A3 (cs) | 2000-06-29 | 2003-05-14 | Glaxosmithkline Biologicals S. A. | Farmaceutický prostředek |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| JP2005504718A (ja) | 2001-01-23 | 2005-02-17 | アヴェンティス パストゥール | 多価髄膜炎菌多糖−タンパク質複合ワクチン |
| AU2007200116A1 (en) * | 2001-04-03 | 2007-02-01 | Glaxosmithkline Biologicals S.A. | Vaccine composition |
| CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| WO2003094960A2 (en) * | 2002-05-14 | 2003-11-20 | Chiron Srl | Mucosal combination vaccines for bacterial meningitis |
| MXPA04011249A (es) | 2002-05-14 | 2005-06-06 | Chiron Srl | Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos. |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| DE60335477D1 (de) | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
| HUE034801T2 (en) * | 2002-11-01 | 2018-02-28 | Glaxosmithkline Biologicals Sa | Drying procedure |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| PT2172213E (pt) * | 2003-01-30 | 2013-06-03 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
| JP2006516609A (ja) * | 2003-01-30 | 2006-07-06 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 粘膜髄膜炎菌性ワクチン |
| AU2004255526A1 (en) | 2003-05-07 | 2005-01-20 | Aventis Pasteur, Inc. | Method of enhanced immunogenicity to meningococcal vaccination |
| GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| EP2364725A3 (en) * | 2003-06-23 | 2012-05-09 | Sanofi Pasteur Inc. | Immunization method against neisseria meningitidis serogroups a and c |
| ATE506963T1 (de) | 2003-10-02 | 2011-05-15 | Novartis Vaccines & Diagnostic | Kombinationsimpfstoffe gegen meningitis |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| CU23404A1 (es) * | 2003-11-19 | 2009-08-04 | Ct Ingenieria Genetica Biotech | Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes |
| GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| JP5718545B2 (ja) | 2004-04-30 | 2015-05-13 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 髄膜炎菌結合体ワクチン接種 |
| GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
| GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
| CN104815327A (zh) | 2005-04-08 | 2015-08-05 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CA2605179A1 (en) | 2005-04-18 | 2006-10-26 | Novartis Vaccines And Diagnostics, Inc. | Expressing hepatitis b virus surface antigen for vaccine preparation |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| PL2878307T3 (pl) | 2005-06-27 | 2020-01-31 | Glaxosmithkline Biologicals S.A. | Kompozycja immunogenna |
| CN1709505B (zh) * | 2005-07-13 | 2010-06-16 | 北京绿竹生物制药有限公司 | 多价细菌荚膜多糖-蛋白质结合物联合疫苗 |
| CN101287488B (zh) * | 2005-09-01 | 2013-01-30 | 诺华疫苗和诊断有限两合公司 | 含血清群c脑膜炎球菌的多价疫苗 |
| CN101355960A (zh) | 2005-10-18 | 2009-01-28 | 诺华疫苗和诊断公司 | 使用α病毒复制子颗粒进行粘膜和全身免疫 |
| GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| GB0607088D0 (en) * | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| PL3017827T3 (pl) * | 2005-12-22 | 2019-04-30 | Glaxosmithkline Biologicals Sa | Szczepionka z koniugatem polisacharydu pneumokokowego |
| AU2006327023A1 (en) * | 2005-12-23 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Conjugate vaccines |
| NO346497B1 (no) * | 2006-01-17 | 2022-09-05 | Arne Forsgren | Overflateeksponert haemophilus influenzae protein (protein E, pE) |
| CA2646993C (en) | 2006-03-22 | 2016-01-26 | Novartis Ag | Regimens for immunisation with meningococcal conjugates |
| TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
| EP1872791A1 (en) | 2006-06-30 | 2008-01-02 | Institut Pasteur | Use of bacterial polysaccharides for biofilm inhibition |
| CN103357003A (zh) | 2006-09-07 | 2013-10-23 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗 |
| US20100074918A1 (en) | 2007-05-02 | 2010-03-25 | Jan Poolman | Vaccine |
| US20100203137A1 (en) | 2007-06-04 | 2010-08-12 | Mario Contorni | Formulation of meningitis vaccines |
| US9610339B2 (en) * | 2007-06-26 | 2017-04-04 | Glaxosmithkline Biologicals, S.A. | Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| US9387239B2 (en) * | 2008-05-30 | 2016-07-12 | U.S. Army Medical Research And Materiel Command | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
| PE20100365A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| ES2614807T3 (es) * | 2010-06-04 | 2017-06-02 | Wyeth Llc | Formulaciones vacunales |
| HUE028452T2 (en) * | 2010-12-14 | 2016-12-28 | Glaxosmithkline Biologicals Sa | Mycobacterium antigenic preparations |
| BR112013017171B1 (pt) | 2011-01-05 | 2019-12-17 | Bharat Biotech International Limited | composição combinada heptavalente estável |
| GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| DE102011118371B4 (de) | 2011-11-11 | 2014-02-13 | Novartis Ag | Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung |
| GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
| DE102011122891B4 (de) | 2011-11-11 | 2014-12-24 | Novartis Ag | Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen |
| EP2592137A1 (en) | 2011-11-11 | 2013-05-15 | Novartis AG | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use |
| CA2863178C (en) * | 2012-01-30 | 2021-04-06 | Serum Institute Of India Ltd. | Immunogenic composition |
| US20150125486A1 (en) * | 2012-03-08 | 2015-05-07 | Novartis Ag | Adjuvanted formulations of pediatric antigens |
| JP2015525794A (ja) | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法 |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| EP2906239A1 (en) | 2012-10-12 | 2015-08-19 | GlaxoSmithKline Biologicals SA | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
| CN104853768B (zh) * | 2012-10-17 | 2019-04-19 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| PE20151720A1 (es) | 2013-03-08 | 2015-12-10 | Crucell Holland Bv | Vacuna acelular contra pertussis |
| WO2015004041A1 (en) * | 2013-07-07 | 2015-01-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic vaccines against streptococcus pneumoniae type 1 |
| CA2919773A1 (en) | 2013-08-05 | 2015-02-12 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
| US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| RU2626532C2 (ru) * | 2015-01-16 | 2017-07-28 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в |
| RU2723045C2 (ru) * | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их получения |
| CA3031797A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| KR102437120B1 (ko) | 2016-08-05 | 2022-08-25 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| KR20190044663A (ko) | 2016-09-02 | 2019-04-30 | 사노피 파스퇴르 인크 | 네이세리아 메닌기티디스 백신 |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| MX2020005779A (es) | 2017-12-06 | 2020-10-28 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos. |
| BR112020014978A2 (pt) | 2018-02-05 | 2020-12-22 | Sanofi Pasteur, Inc. | Composição de conjugado polissacarídeo-proteína pneumocócico multivalente |
| CA3089007A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| TW202011985A (zh) | 2018-04-18 | 2020-04-01 | 韓商Ｓｋ生物科學股份有限公司 | 肺炎鏈球菌的莢膜多醣類以及其免疫原性接合體 |
| KR102827174B1 (ko) * | 2018-04-30 | 2025-06-27 | 머크 샤프 앤드 돔 엘엘씨 | 디메틸술폭시드 중의 동결건조된 돌연변이체 디프테리아 독소의 균질 용액을 제공하는 방법 |
| KR20200005458A (ko) | 2018-07-06 | 2020-01-15 | 주식회사 유바이오로직스 | 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물 |
| CN113271967A (zh) * | 2018-11-10 | 2021-08-17 | 巴拉特生物技术国际有限公司 | 多价糖缀合物免疫原性组合物 |
| KR20240169145A (ko) | 2018-12-19 | 2024-12-02 | 머크 샤프 앤드 돔 엘엘씨 | 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법 |
| AU2020277403A1 (en) | 2019-05-20 | 2022-01-06 | Soligenix, Inc. | Compositions and methods of manufacturing trivalent filovirus vaccines |
| CN111821432B (zh) * | 2020-08-05 | 2022-10-18 | 北京智飞绿竹生物制药有限公司 | 一种多价肺炎球菌结合疫苗 |
| WO2025109417A1 (en) * | 2023-11-21 | 2025-05-30 | Panacea Biotec Limited | Immunogenic composition of haemophilus influenzae conjugated to protein d |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057685A (en) * | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| EP0027888B1 (en) * | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4673574A (en) * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4459286A (en) * | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| JPS6061288A (ja) * | 1983-09-13 | 1985-04-09 | Fuji Photo Film Co Ltd | 感熱記録材料 |
| US4808700A (en) * | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| GB8516442D0 (en) | 1985-06-28 | 1985-07-31 | Wellcome Found | Cloned antigen |
| GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
| GB8914122D0 (en) | 1989-06-20 | 1989-08-09 | Wellcome Found | Polypeptide expression |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| WO1993021769A1 (en) | 1992-05-06 | 1993-11-11 | President And Fellows Of Harvard College | Diphtheria toxin receptor-binding region |
| EP2156845A1 (en) * | 1992-05-23 | 2010-02-24 | GlaxoSmithKline Biologicals SA | Combined vaccines comprising hepatitis B surface antigen and other antigens |
| AU671649B2 (en) | 1992-06-18 | 1996-09-05 | President And Fellows Of Harvard College | Diphtheria toxin vaccines |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| DK0594950T3 (da) * | 1992-10-27 | 1999-09-13 | American Cyanamid Co | Pædiatrisk kombinationsvaccine med forbedret immunogenicitet af hver vaccinekomponent |
| US5849301A (en) * | 1993-09-22 | 1998-12-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents |
| ATE254475T1 (de) | 1993-09-22 | 2003-12-15 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5869058A (en) * | 1994-05-25 | 1999-02-09 | Yeda Research And Development Co. Ltd. | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
| US6455673B1 (en) * | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| CN1146444C (zh) | 1995-06-23 | 2004-04-21 | 史密斯克莱·比奇曼生物公司 | 含有吸附于磷酸铝上的多糖偶联抗原的疫苗组合物 |
| US5997881A (en) | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
| AU5873498A (en) | 1997-01-30 | 1998-08-25 | Imperial College Of Science, Technology And Medicine | Mutant (msbb) or (htrb) genes |
| ATE316797T1 (de) * | 1997-09-15 | 2006-02-15 | Sanofi Pasteur Msd | Verfahren zur herstellung multivalenter impfstoffe |
| US5965714A (en) * | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
| US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
| GB9925559D0 (en) * | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
| FR2806304B1 (fr) * | 2000-03-17 | 2002-05-10 | Aventis Pasteur | Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie |
| CZ20024224A3 (cs) | 2000-06-29 | 2003-05-14 | Glaxosmithkline Biologicals S. A. | Farmaceutický prostředek |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| AU2003257003A1 (en) * | 2002-07-30 | 2004-02-16 | Baxter Healthcare S.A. | Chimeric multivalent polysaccharide conjugate vaccines |
| GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| GB0500787D0 (en) * | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| PL2878307T3 (pl) * | 2005-06-27 | 2020-01-31 | Glaxosmithkline Biologicals S.A. | Kompozycja immunogenna |
| PL3017827T3 (pl) * | 2005-12-22 | 2019-04-30 | Glaxosmithkline Biologicals Sa | Szczepionka z koniugatem polisacharydu pneumokokowego |
| GB0607088D0 (en) * | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| AU2006327023A1 (en) * | 2005-12-23 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Conjugate vaccines |
| GB0700136D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
| GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2008111374A1 (ja) * | 2007-03-14 | 2008-09-18 | Konica Minolta Business Technologies, Inc. | 情報埋め込み方法、そのプログラムおよび情報埋め込み装置 |
| US20100074918A1 (en) * | 2007-05-02 | 2010-03-25 | Jan Poolman | Vaccine |
| US20100203137A1 (en) * | 2007-06-04 | 2010-08-12 | Mario Contorni | Formulation of meningitis vaccines |
| US9610339B2 (en) * | 2007-06-26 | 2017-04-04 | Glaxosmithkline Biologicals, S.A. | Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates |
-
2001
- 2001-06-27 CZ CZ20024224A patent/CZ20024224A3/cs not_active IP Right Cessation
- 2001-06-27 UY UY26801A patent/UY26801A1/es not_active IP Right Cessation
- 2001-06-27 BR BR122012003821A patent/BR122012003821B8/pt not_active IP Right Cessation
- 2001-06-27 HU HU0301413A patent/HU228384B1/hu unknown
- 2001-06-27 DK DK07116669.8T patent/DK1946769T3/da active
- 2001-06-27 MX MXPA03000198A patent/MXPA03000198A/es active IP Right Grant
- 2001-06-27 ES ES07116669T patent/ES2385100T3/es not_active Expired - Lifetime
- 2001-06-27 CN CN200910174266.7A patent/CN101708333B/zh not_active Expired - Lifetime
- 2001-06-27 SI SI200131012T patent/SI1946769T1/sl unknown
- 2001-06-27 IL IL15350601A patent/IL153506A0/xx unknown
- 2001-06-27 PT PT01960390T patent/PT1296715E/pt unknown
- 2001-06-27 DZ DZ013399A patent/DZ3399A1/xx active
- 2001-06-27 PL PL360265A patent/PL210015B1/pl unknown
- 2001-06-27 AU AU8189501A patent/AU8189501A/xx active Pending
- 2001-06-27 AP APAP/P/2002/002700A patent/AP1695A/en active
- 2001-06-27 CA CA2412497A patent/CA2412497C/en not_active Expired - Lifetime
- 2001-06-27 US US10/312,090 patent/US20030180316A1/en not_active Abandoned
- 2001-06-27 EP EP10178451A patent/EP2277541A1/en not_active Withdrawn
- 2001-06-27 CA CA2783274A patent/CA2783274C/en not_active Expired - Lifetime
- 2001-06-27 KR KR1020027017928A patent/KR100837917B1/ko not_active Expired - Lifetime
- 2001-06-27 EP EP10178449A patent/EP2279748A1/en not_active Withdrawn
- 2001-06-27 EA EA200501070A patent/EA011480B1/ru not_active IP Right Cessation
- 2001-06-27 ES ES01960390.1T patent/ES2375704T5/es not_active Expired - Lifetime
- 2001-06-27 EP EP07116669A patent/EP1946769B1/en not_active Expired - Lifetime
- 2001-06-27 PE PE2001000629A patent/PE20020126A1/es not_active Application Discontinuation
- 2001-06-27 CN CN018146198A patent/CN1449293B/zh not_active Expired - Lifetime
- 2001-06-27 SK SK1843-2002A patent/SK288007B6/sk not_active IP Right Cessation
- 2001-06-27 AT AT01960390T patent/ATE534402T1/de active
- 2001-06-27 WO PCT/EP2001/007288 patent/WO2002000249A2/en not_active Ceased
- 2001-06-27 EP EP01960390.1A patent/EP1296715B2/en not_active Expired - Lifetime
- 2001-06-27 DK DK01960390.1T patent/DK1296715T4/en active
- 2001-06-27 PT PT07116669T patent/PT1946769E/pt unknown
- 2001-06-27 KR KR1020087013186A patent/KR100898845B1/ko not_active Expired - Lifetime
- 2001-06-27 BR BRPI0112057A patent/BRPI0112057B8/pt not_active IP Right Cessation
- 2001-06-27 HU HU1000593A patent/HU227893B1/hu unknown
- 2001-06-27 UA UAA200604994A patent/UA85853C2/uk unknown
- 2001-06-27 PL PL393584A patent/PL393584A1/pl unknown
- 2001-06-27 JP JP2002505030A patent/JP4870895B2/ja not_active Expired - Lifetime
- 2001-06-27 EA EA200201240A patent/EA006313B1/ru not_active IP Right Cessation
- 2001-06-27 UA UA20021210397A patent/UA76952C2/uk unknown
- 2001-06-27 OA OA1200200395A patent/OA12302A/en unknown
- 2001-06-27 KR KR1020077019832A patent/KR20070091698A/ko not_active Ceased
- 2001-06-27 AU AU2001281895A patent/AU2001281895C1/en not_active Expired
- 2001-06-27 NZ NZ523319A patent/NZ523319A/en not_active IP Right Cessation
- 2001-06-27 EG EG20010701A patent/EG24742A/xx active
- 2001-06-27 MY MYPI20013027 patent/MY133981A/en unknown
- 2001-06-27 HU HU1000594A patent/HU227613B1/hu unknown
- 2001-06-27 SI SI200131007T patent/SI1296715T2/sl unknown
-
2002
- 2002-12-17 IL IL153506A patent/IL153506A/en active IP Right Grant
- 2002-12-20 NO NO20026175A patent/NO332495B1/no not_active IP Right Cessation
- 2002-12-26 MA MA26980A patent/MA25824A1/fr unknown
- 2002-12-28 BG BG107422A patent/BG66238B1/bg unknown
-
2009
- 2009-11-06 BG BG10110518A patent/BG66249B1/bg unknown
-
2010
- 2010-03-15 JP JP2010057779A patent/JP5346308B2/ja not_active Expired - Lifetime
-
2012
- 2012-01-30 CY CY20121100103T patent/CY1112280T1/el unknown
- 2012-04-04 US US13/439,829 patent/US9233151B2/en not_active Expired - Fee Related
- 2012-06-15 CY CY20121100549T patent/CY1112915T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9233151B2 (en) | Vaccine composition | |
| CA2727715C (en) | Vaccine composition | |
| AU2007200116A1 (en) | Vaccine composition | |
| ZA200300755B (en) | Multivalent vaccine composition. | |
| AU2005203302A1 (en) | Vaccine composition | |
| HK1114782A (en) | Multivalent vaccine composition with reduced dose of haemophilus influenzae type b | |
| HK1114781B (en) | Multivalent vaccine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Expiry date: 20210627 |